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Introduction
Pneumonia is one the most common causes of hospital 
admissions exceeding more than one-million cases per year, 
contributing to 3.4% of inpatient mortality [1,2]. There are 
several studies conducted to compare different antibiotics for 
the treatment of community acquired pneumonia, however 
there are limited data from large trials comparing ceftriaxone 
plus azithromycin to fluoroquinolone therapy for inpatient 
treatment of CAP. The current IDSA guidelines published in 
2007 recommend treatment of CAP in non-ICU patient with 
fluoroquinolone alone or beta-lactam plus macrolide [3]. 
Arnold and colleagues [4] compared treatment of pneumonia 
with current guidelines to non-adherence to guidelines. The 
study concluded that adhering to the guidelines decreased 
the mortality rate, length of hospital stay, and time to clinical 
stability. Wang and colleagues compared fluoroquinolone 
based therapy to penicillin based therapy in the treatment of 
community acquired pneumonia in an outpatient setting [5].
The study concluded that the treatment failure rates were less 
in fluoroquinolone based therapy compared to penicillin based 
therapy, and no difference in hospitalizations, emergency visits 
or 30-day mortality. A recent cluster-randomized, crossover 
trial concluded that beta-lactam monotherapy was non-
inferior to the beta-lactam plus macrolide or fluoroquinolone 
monotherapy [6] .
Better knowledge of optimal treatment is critical to improve 
outcomes. Our study is unique in comparing 30-day all-cause 
mortality benefit using ceftriaxone plus azithromycin to 
fluoroquinolones in a large multicenter cohort for treatment of 
CAP. 
Methods
We conducted a retrospective review from January 2008 to 
December 2012 including inpatients 18 years of age or older who 
were hospitalized with the diagnosis of community acquired 
pneumonia based on ICD-9 discharge diagnosis. Participating 
centers included four large health care institutions located in 
Maryland, Michigan, Missouri, and Texas. Information about 
patients’ sex, age, race, discharge diagnosis, cultured organism, 
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hospital length of stay, readmission status, and mortality within 
30 days was collected from each of the four hospitals’ electronic 
medical records (EMR).  Information was obtained from each 
participating centers’ EMR which was then entered into a 
single database. This database included approximately 70,000 
patients. Data was de-identified and coded using explicit data 
specifications and uploaded into one large database. The study 
protocol was approved by the institutional review board (IRB) 
at each participating institution. Teleconferences, enrollments 
reports, and data audits were conducted between the four study 
sites to ensure uniform data collection.
All hospitalized patients in these hospitals between January 
1, 2008 and December 30, 2012 with a discharge diagnosis 
of pneumonia were identified. Patients were included in the 
present study if: 1) They were aged ≥18 years; 2) They had 
received either ceftriaxone plus azithromycin, levofloxacin, 
or moxifloxacin for the duration of the hospitalization with no 
other antibiotics administered. Exclusion criteria included: 1) 
Patients who received other antimicrobial agents; 2) Patients 
with diagnosis of pneumonia with no information on therapy; 3) 
Patients who received both therapies. The primary outcome of 
the study was 30-day all-cause mortality. In hospital mortality 
was used as a marker for 30-day mortality, as our database 
was unable to assess 30-day mortality. The patients’ severity of 
comorbidities was assessed using Charlson comorbidity index. 
Statistical Methods
Univariate statistical analysis was used to test the association 
of demographic and clinical characteristics with all-cause 
discharge mortality. Categorical variables were analyzed using 
the Chi-squared test or Fisher’s exact test. Continuous variables 
were analyzed using an unpaired t-test. All variables with a 
p-value < 0.05 in the univariate analysis were included into the 
multivariate logistic regression. The stepwise selection method 
was performed to generate the final model (P≤0.05 required 
for variable entry, P≤0.10 required for variable removal). All 
p-values were two-sided. Analyses were performed by using SAS 
9.4.
Results
A total of 21,800 patients met our inclusion criteria for CAP, 
however 1,740 patients were excluded as they received both 
beta-lactams and fluoroquinolones. The study included 20,600 
patients. 11,201 patients (55.84%) received ceftriaxone with 
azithromycin, and 8,859 (44.16%) received fluoroquinolone 
therapy. Demographic and clinical characteristics of patients 
are shown in Table 1. The mortality rate for patients who 
received fluoroquinolone therapy was lower compared to the 
patients who received ceftriaxone plus azithromycin (3.56% vs 
6.71%, p-value <0.001).
Discussion
Our study demonstrated that the use of fluoroquinolone therapy 
for treatment of CAP decreased 30-day all-cause mortality 
compared to ceftriaxone plus azithromycin. Despite high 
comorbidity index in the cohort treated with fluoroquinolones, 
those treated with fluoroquinolones had better outcomes 
than those treated with ceftriaxone plus azithromycin. Our 
study is unique in several ways. First, the large sample size 
of this study strengthens the analysis as well as significantly 
different variables.  Second, there have been limited studies 
conducted to compare ceftriaxone plus azithromycin to 
fluoroquinolone therapy with respect to mortality. The present 
study only included patients treated with these agents. Third, 
the data is collected from four different hospitals which are 
located in various locations throughout United States. Despite 
various geographic locations of the hospitals with different 
antibiograms, fluoroquinolones had mortality benefit over 
ceftriaxone plus azithromycin. Our study results are dis-
concordant with the meta-analysis of randomized controlled 
trials by Vardakas et al [7]. Their interpretation did reveal that 
fluoroquinolone therapy has a higher success rate in treatment 
of pneumonia compared to beta-lactam therapy with and 
without macrolides, however the data showed that there was no 
mortality benefit with fluoroquinolones. One of the possibilities 
several studies favor fluoroquinolone therapy is that there is 
different spectrum of coverage of fluoroquinolones including 
MSSA, gram-negative coverage including anti-pseudomonal 
activity for some agents such as levofloxacin, as well as 
atypical coverage [8]. Another factor may be the emergence of 
Streptococcus pneumonia which are resistant to macrolides. 
Multiple studies favor monotherapy with a fluoroquinolone over 
combination therapy. Querol-Ribelles et al. in a prospective 
observational cohort study showed improved mortality in 
patients treated with levofloxacin compared to those treated 
with combination therapy of ceftriaxone plus clarithromycin 
[9]. Another meta-analysis of randomized controlled trials by 
Raz-Pasteur et al. did not reveal a mortality benefit between 
monotherapy and combination therapy with a beta-lactam; 
however, the study was significant for decreased failure rates 
of therapy and treatment discontinuation in those receiving 
monotherapy with a fluoroquinolone [10]. Limitations of the 
present study include that it was a retrospective observational 
study with information gathered using only electronic medical 
records. The immune status of patients were unable to be 
obtained.  Pneumonia severity index and CURB-65 scores, 
which are markers of disease severity, were unable to be 
obtained. Without calculating these scores, we cannot rule out 
the possibility of confounding by indication of the use of therapy 
based on disease severity. Many patients with CAP have no 
organism identified further limiting comparison of outcomes 
between the groups. Another limitation is that it is possible that 
activity against organisms isolated were different in one group 
versus another, which was not evaluated in this study.  Finally, 
mortality during hospitalization was obtained, we did not have 
information on 30-day mortality, thus in hospital mortality was 
used as a marker for 30-day mortality.
Conclusions
Our study showed statistically significant lower 30-day mortality 
using fluoroquinolone therapy compared to ceftriaxone plus 
azithromycin for treatment of community acquired pneumonia. 
Further randomized controlled trials would be needed to 
support this evidence.
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Table 1 Demographics and clinical characteristics and outcomes of patients admitted to the hospital with CAP
Patient characteristics Fluoroquinolone therapy n (%) Ceftriaxone plus azithromycin n (%) p-value 
Total patients  8859 (44.16) 11201(55.84) 
 
Age 
     Mean Age 
 
64.2764 ± 17.1823 
 
59.5046 ± 18.3095 
 
<0.001 
     >65 years 4266 (48.15) 6660 (59.46) <0.001 
     <65 years 4593 (51.85) 4541 (40.84) <0.001 
Gender 
     Male 










     White 
     Black 
     Hispanic 
     Asian 
     Other 
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     DM 
     Transplant 
     Asthma 
     COPD 
     Sickle Cell 
     CAD 
     Asplenia 
     CKD 
     Heart Failure 
     Cancer 








































Charlson score 4.0227 ± 2.2527 3.5011 ± 2.2537 <0.0001 
Mortality  315 (3.56%) 752 (6.71%) <0.0001 
 
